ONE Holdings, Corp. (OTCBB: ONEZ), a green process manufacturer of high-quality health supplements, organic fertilizers and pesticides, announces that its subsidiary Green Planet Bioengineering CO., LTD. (OTCBB: GPLB) has filed an invention patent for Sarcandra Glabra.

The patent specifically covers the process and application of extracting Isofraxidin and Flavonoid compounds synchronously from Sarcandra Glabra. The new process will dramatically increase the extraction rate from Sarcandra Glabra, and also significantly improve the medicinal yield in the process. This will accelerate the company's time to market its over-the-counter products. Up until now, Sarcandra Glabra extraction was limited to a single composition. The company expects to achieve commercial production by the fourth quarter of this year.

"This is a very exciting technical development because of the direct economic benefit ONE will reap from the process. It dramatically increases our time to market in the high margin over-the-counter business. We will be launching OTC products in Q4 of this year and look to see significant increase in our net profits as a result," stated Mr. Min Zhao, President of ONE's China operations.

"This is another great step forward for ONE. Increasing profitability and product expansion is our key focus and this new process will achieve both dramatically by enabling us to more effectively enter the over-the-counter market next year," stated ONE's CEO Marius Silvasan.

For a full list of Green Planet's products please visit the Company's website: http://www.greenplanetbio.com/

About ONE Holdings, Corp.

ONE Holdings, Corp. ("ONE") (OTCBB: ONEZ) (www.onehcorp.com), headquartered in Miami, FL, is a company utilizing green processes specialized in raw chemicals and herbal extracts, natural supplements and organic products. ONE is focused on the Asia Pacific region. Key products include widely recognized Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. ONE's growth plan targets an aggressive acquisition driven strategy supported by strong organic growth. Through ONE, small private companies gain access to capital, experienced management and strategic insight. ONE builds strong synergies amongst all subsidiaries to enhance shareholder value. ONE is working with each subsidiary to promote organic and acquisition driven growth.

About Green Planet

Green Planet Bioengineering CO., LTD. ("Green Planet") (http://www.greenplanetbio.com) (OTCBB: GPLB), a subsidiary of ONE Holdings, Corp. (OTCBB: ONEZ), is a high-tech bioengineering enterprise that engages in research & development, production and sale of various extracts from tobacco leaves residue destined for health supplements and organic agricultural products. Green Planet is headquartered in Miami, FL with its main operation located in Sanming and Fuzhou, China. Since founded in 2005, Green Planet offers a full range of high quality bio-ecological products which include raw chemical materials such as CoQ10 and Solanesol, organic fertilizers and pesticides and organic health nutrients and supplements. The Company's unique position in the bioengineering industry comes from its R&D using patented cutting-edge methods to create abundant downstream products ranging from plant indigenous medicine, pharmaceutical intermediates to a long list of eco-friendly products.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Green Planet Bioengineering, Co., Ltd. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and Green Planet Bioengineering, Co., Ltd. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Company Contact: Jeanne Chan Senior VP Tel. +877.544.2288 jchan@onehcorp.com

Green Planet Bioengineer... (PK) (USOTC:GPLB)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024 Click aqui para mais gráficos Green Planet Bioengineer... (PK).
Green Planet Bioengineer... (PK) (USOTC:GPLB)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024 Click aqui para mais gráficos Green Planet Bioengineer... (PK).